Invited Speaker

Ukrain (Nsc 631570) In The Treatment Of Prostate Cancer
Wassil Nowicky and Askold Nowicky
Austria

Ukrain (NSC 631570) inhibits tubulin polymerisation and induces apoptosis in cancer cells by activating the intrinsic mitochondrial cell death pathway while leaving normal cells undamaged. In the tests on prostate cancer cell line LNCaP, researchers from Rochester University, USA revealed Ukrain to induce the G2M accumulation of cancer cells but not of normal human keratinocytes HaCaT cells. The researchers also observed an upregulation of CDK inhibitor p27 in cancer cells.

This malignocytolytic effect of Ukrain in prostate cancer was confirmed in clinic. More than 150 prostate cancer patients have been successfully treated with Ukrain so far. 74 patients were involved in a controlled study in Germany. These patients had already been treated according to all conventional therapy protocols, and due to relapse and/or progression of the disease had no further conventional options available. They were treated with Ukrain and partially with local hyperthermia. The following results were obtained: complete remission in 73% of patients and partial remission in 22%, with only 5% of patients showing no effect on the progress of the disease. At the beginning of the therapy, PSA value can increase. It decreases as the tumor responses to the therapy.